Navigation Links
Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
Date:9/2/2008

ed in the study, which is being conducted in the United States, Canada, Australia and India. Patients were randomized into three treatment groups, with one group receiving bortezomib alone and two groups receiving bortezomib in combination with mapatumumab (10 mg/kg or 20 mg/kg). Approximately 43% (15/35) of the patients in the group receiving bortezomib alone were randomized contemporaneously with randomization of the group receiving a combination of bortezomib and mapatumumab at 10 mg/kg. The remaining 57% (20/35) of the patients in the group receiving bortezomib alone were randomized contemporaneously with randomization of the group receiving a combination of bortezomib and mapatumumab at 20 mg/kg. The primary objective of the study is to evaluate disease response to mapatumumab in combination with bortezomib, versus bortezomib alone, in patients with relapsed or refractory multiple myeloma. Secondary objectives include evaluation of progression-free survival, safety and tolerability, and plasma concentrations of mapatumumab for use in a population pharmacokinetic analysis.

Patients participating in the study had received a median of 2 previous cancer treatment regimens. At baseline, 17.1% (6/35) of patients in the treatment group receiving bortezomib alone had Stage 3 disease, vs. 40.6% (13/33) in the group receiving the combination of bortezomib and mapatumumab at 10 mg/kg, and 19.4% (7/36) in the group receiving the combination of bortezomib and mapatumumab at 20 mg/kg. The initial data show that mapatumumab was well tolerated and could be administered safely and repetitively in combination with bortezomib, with no evidence of increased toxicity in patients receiving the combination of bortezomib and mapatumumab, vs. patients receiving bortezomib alone.

Overall, based on initial data, disease response was comparable among the three treatment groups, including the following findings:

-- Three complete responses (8.3%; N=36) were observed am
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Sept. 1, 2015 Taiwan,s ... press conference in Taipei on  ... new Vaucarrin™ platform, a targeted drug delivery technology that ... This event was part of a joint press conference ... NanoTech Inc. (GNT), showcasing GNT,s latest edible gold-based food ...
(Date:9/1/2015)... 1, 2015 Agena Bioscience TM today announced ... , a commercial and financial hub from which many biotech ... testing laboratories in mainland China . ... Bioscience,s global sales with almost sixty MassARRAY ® Systems ... will allow us to expand our reach and foster ...
(Date:9/1/2015)... , 1. September 2015 In ... von 2.500 Mitarbeitern hat die SHL Group schnell ... konstantes und rapides Wachstum auf dem Markt ... die Produktivität und das Management von SHL wieder. ... SHL ist weltweit führend in Design und ...
Breaking Medicine Technology:GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 3GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 4GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 5Agena Bioscience Opens Office in Shanghai, China 2SHL Group erreicht wichtigen Markstein von 3.000 Mitarbeitern 2
... N.Y., Aug. 17, 2011 Polymedco is pleased ... Colorectal Cancer Screening in Integrated Health Care Systems" ... Burley, Juan Reyes, Michael Oehrli, and Cindy Caldwell ... screening program for Colorectal cancer (CRC) at Kaiser ...
... 17, 2011  ConvaTec, a world-leading developer and marketer ... today announced the appointments of Charles Cerminara and James ... has been appointed Vice President and General Manager, Greater ... on the growth of the Chinese market and to ...
Cached Medicine Technology:Polymedco Announces Publication in Epidemiologic Reviews 2ConvaTec Announces Asia-Pacific Leadership Appointments 2
(Date:9/1/2015)... (PRWEB) , ... September 01, ... ... seeking better therapeutic options to efficiently cure and prevent different malignancies. Some ... cancers have different pathophysiological properties due to which distinctive approach is necessary ...
(Date:9/1/2015)... ... September 01, 2015 , ... Negative pressure wound ... a wound to remove exudates, fluid, and infectious materials to prepare the wound ... devices, disposable devices, and canisters, etc.) is projected to expand continuously through 2021. ...
(Date:9/1/2015)... ... September 01, 2015 , ... The ... Information Management has been granted continued accreditation based on a successfully completed ... ÔÇťAchieving and maintaining this accreditation takes the involvement and dedication of each ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... government entities, announced today that it has hired Scott Sanderson, an experienced business ... this capacity, Sanderson will be responsible for establishing and managing new client relationships ...
(Date:9/1/2015)... ... 2015 , ... WorkCare, Inc., a national occupational health services ... as an Associate Medical Director. , WorkCare specializes in workforce health protection ... abroad. , Dr. Nelson has a diverse background. He trained in sports ...
Breaking Medicine News(10 mins):Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3
... Seeking Feedback on Revisions to Standards , , WASHINGTON, ... comprehensive review of its standards, URAC , ... for public comment on revisions to its Health ... Security standards . URAC welcomes purchasers, policy ...
... June 18 /PRNewswire-Asia-FirstCall/ -- Jiangbo,Pharmaceuticals Enterprises, Inc. (OTC ... company with its principal operations in the,People,s Republic ... the China New,Drugs Trade Fair from June 26 ... Exhibition Center, and also plans to launch a ...
... , DENVER, June 18 DaVita Inc. (NYSE: ... those diagnosed with chronic kidney disease (CKD), today announced the ... Work for in Colorado Program. DaVita(R) is the only ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO ) , , "We ...
... ... Southeast Asia,s largest private hospital and one of the world,s top medical travel destinations, ... Quality Class (TQC) award for 2008. , ... Bangkok, Thailand (PRWEB) June 18, 2009 -- Bumrungrad International ...
... ... has been validated by ACHC as an organization dedicated to quality patient services, and ... ... -- Homefront Diabetic Services proudly announces its award of accreditation status by the Accreditation ...
... approach to choosing the best treatment options for early breast ... in a report from the 11th St Gallen conference. ... Annals of Oncology [1] today (Thursday 18 June), and ... from the conference of more than 4,800 participants from 101 ...
Cached Medicine News:Health News:Public Comment Period Open for HIPAA Privacy and Security Standards 2Health News:Public Comment Period Open for HIPAA Privacy and Security Standards 3Health News:Public Comment Period Open for HIPAA Privacy and Security Standards 4Health News:Jiangbo Pharmaceuticals to Attend the 44th China New Drugs Trade Fair in Tianjin 2Health News:Jiangbo Pharmaceuticals to Attend the 44th China New Drugs Trade Fair in Tianjin 3Health News:DaVita Named One of Best Companies to Work for in Colorado 2Health News:Bumrungrad International the first private hospital to be awarded Thailand Quality Class (TQC) for organizational excellence 2Health News:Bumrungrad International the first private hospital to be awarded Thailand Quality Class (TQC) for organizational excellence 3Health News:Homefront Diabetic Services Completes Accreditation with ACHC 2Health News:St. Gallen consensus 2009: A radically different approach to treating early breast cancer 2Health News:St. Gallen consensus 2009: A radically different approach to treating early breast cancer 3
CataRhex PRO the portable cataract extraction system with automated capsulotomy....
Phacoemulsification system is a complete anterior segment surgical instrument. Its simplified design and unique innovations provide optimal surgical performance....
Aaron Burr II with disposable 1mm burr for corneal rust ring removal and a diamond burr tip for polishing the pterygium bed after surgical removal and for lid margin lesions....
Algerbrush II corneal rust ring remover battery powered...
Medicine Products: